Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 13/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6495922 | 0.85 | NPC1 (0.50) | CRHR1CNR2CNR1NPC1 | |
| SCHEMBL6497711 | 0.84 | NPC1 (0.49) | CRHR1CNR2CNR1NPC1 | |
| SCHEMBL6501000 | 0.82 | CRHR1 (0.43) | CRHR1CNR2CNR1 | |
| SCHEMBL6495416 | 0.80 | CRHR1 (0.44) | CRHR1 | |
| SCHEMBL6071090 | 0.79 | CRHR1 (0.42) | CRHR1NPC1 | |
| SCHEMBL6497957 | 0.79 | CRHR1 (0.43) | CRHR1CNR2CNR1 | |
| SCHEMBL6504882 | 0.73 | CRHR1 (0.50) | CRHR1NPC1 | |
| SCHEMBL6496618 | 0.70 | MAPT (0.38) | CRHR1NPC1 | |
| SCHEMBL7048739 | 0.70 | NPC1 (0.46) | CRHR1NPC1 | |
| SCHEMBL6498696 | 0.70 | CRHR1 (0.39) | CRHR1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026317-B2 | Pyrazolotriazines as CRF antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-04-11 | — | — | US | disclosed |
| US-6960583-B2 | Pyrazolotriazines as CRF antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-01 | — | — | US | disclosed |
| US-20040176376-A1 | Pyrazolotriazines as CRF antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176376-A1 | Pyrazolotriazines as CRF antagonists | CRHR1, CRHR2, CRH | CRHR1 1/4885HSD11B1 398/4885CNR2 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.